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Idiopathic Juxtafoveal Telangiectasia
Abstract
Idiopathic Juxtafoveal Telangiectasia (IJT), also called Idiopathic Macular 
Telangiectasia, is a group of disorders with varying etiologies that share the 
common finding of telangiectatic vessels in the juxtafoveal region of the 
macula. IJT is classically divided into three groups, each with clinically dis-
tinct findings and differing etiologies. Type I typically occurs unilaterally, 
primarily affects males, and is thought to be congenital. Vision loss usually 
results from macular edema. The most common type, II, normally presents 
bilaterally, has no sex predilection, and is thought to be acquired. Vision 
loss occurs not from edema, but from retinal atrophy. The last type, III, is 
extremely rare and is usually found in association with coexisting systemic 
or neurological disorders. Vision loss most likely results from retinal isch-
emia. This paper will describe classifications, clinical findings, etiologies, 
and treatment options of IJT along with patient case figures. 
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INTRODUCTION
IJT is a condition comprised of three classical divisions, each with different clinical findings, etiologies, and patient 
demographics. They do share a common feature of capillary abnormalities in the juxtafoveal region that appear on 
fluorescein angiography as dilated or telangiectatic capillary changes.1 IJT can easily be confused for other condi-
tions, and these abnormal capillary findings must be separated from those resultant from other conditions such as 
diabetes, carotid occlusive disease, retinal vein occlusion, radiation therapy, and others.2 The classification also does 
not include Coat’s disease, which has more widespread retinal telangiectatic changes. However, Coat’s disease and 
IJT Type I could be subsets of the same condition that exists as a spectrum of disease.3
GASS AND BLODI CL ASSIFICATION
Gass and Owakawa first coined the term IJT in 1982 and initially categorized the condition in four different 
classes.1 Gass and Blodi later revisited the topic in 1993 in a follow up report of the initial work done by Gass and 
Owakawa at which time they modified the classification into three main categories, each with separate unrelated 
etiologies and two subsets: Type IA and B, Type IIA and B, and Type IIIA and B. Additionally, Type II was further 
divided into five stages.3 Clinical observations and fluorescein angiography (FA) findings formed the basis of the 
grouping in this system. 
Type I
Type I IJT presented with easily visible retinal telangiectasia often accompanied with exudation and macular ede-
ma, with vision loss resulting from the latter. Gass and Blodi broke down Type I IJT based on the extent of telangi-
ectasia as defined by the number of involved clock hours around the fovea. Type IA had more than two clock hours 
of telangiectasia while Type IB had less than two clock hours (Figure 1). 
Figure 1: Easily visible retinal telangiectasia in a patient with Gass and Blodi Type IA IJT, or Yanuzzi et al.’s Type I 
aneurysmal telangiectasia. 
In Gass and Blodi’s study, Type IA patients consisted of 31 subjects with a high male predilection (28 male) and a 
mean patient age of 37. Entering visual acuity ranged from 20/20 to 20/200. They found Type IA to be unilateral in 
30 of the 31 cases. Clinical findings varied between patients, but generally presented with easily visible retinal telan-
giectasia, macular edema, and exudation. Type IA patients lacked right angle veins, superficial crystalline deposits, 
intraretinal pigmentary plaques, or subretinal neovascularization (SRNV). 
Fluorescein angiography showed quick filling of the irregular telangiectatic vessels around the fovea. These ap-
peared as an irregular round zone of capillary aneurysms and dilated capillaries located temporal to the fovea in 
94% of the cases. They noted minimal capillary occlusion or capillary dropout. Late stage FA revealed intraretinal 
staining as the abnormal vessels continued to leak. 
C A NA D I A N  JO U R NA L  o f  O P T O M E T RY    |    R EV U E  C A NA D I E N N E  D ’O P T O M É T R I E     VO L .  7 9   NO.  326
RESEARCH
Only eight patients in the study displayed the less prevalent Type IB IJT. Again, a high gender predilection existed with 
seven of the patients being male. The average age was 42. All but two eyes (20/25 and 20/30) exhibited 20/20 visual acuity.
Findings were again unilateral in most cases (seven out of eight) but were confined to two clock hours or less of still 
easily visible telangiectasia. A few flecks of exudates occurred in most cases, but less than that seen with Type IA. 
Fluorescein angiography showed early filling of one to four capillary aneurysms and of the irregular capillaries fol-
lowed by late staining around the rare aneurysms. 
Type II
Unlike Type I, Type II IJT rarely displays macular edema and exudation. In these patients, outer retina atrophy is 
the main cause of vision loss. Gass and Blodi classified Type II into subsets A and B based on the age of presentation. 
Type IIA consisted of 92 patients with equal gender incidence and an average age of 55 years. Entering visual 
acuity ranged from 20/15 to hand motion. Presentation was bilateral, though often asymmetric, in 90 out of 
92 patients. Unlike Type I, these patients exhibited either minimal, poorly visible, or no clinically discernible 
telangiectasia. These abnormal capillaries would light up early with FA and then gradually stain in late stages 
(Figure 2). All cases involved the temporal parafovea. Additional clinical findings of Type IIA included right 
angle veins, pigmented retinal plaques, superficial crystalline deposits, and SRNV (Figures 3 and 4). Gass and 
Blodi also described what appeared to be foveal atrophy on funduscopic evaluation, similar to that of a lamellar 
macular hole (Figure 4). 
Figure 2: Early phase FA (left) shows the classic finding of punctate hyperfluorescence temporal to the fovea and the atypical 
location of more areas superior to the macula. Late phase reveals increased hyperfluorescence (right). 
Gass and Blodi developed five stages of Type IIA. In their findings, visual acuity remained unaffected in Stages 1 and 
2. Patients typically became symptomatic in Stage 3, and Stage 5 resulted in poor visual acuity.
• Stage 1: Biomicroscopically normal fundus, minimal or no capillary abnormality in early FA,  
 mild staining in late FA 
• Stage 2: Slight graying of perifoveal retina, minimal or no visible telangiectasia,  
 capillary telangiectasia in early FA 
• Stage 3: Right angle veins 
• Stage 4: Pigmented retinal plaques 
• Stage 5: Subretinal neovascularization
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Figure 3: Gass and Blodi Type IIA Stage 4 (note the prominent right angle vein stretching from the superior temporal venous 
branch directly to the pigment plaque), or Yanuzzi et al.’s Type II perifoveal telangiectasia, non-proliferative stage.
Figure 4: Type II IJT with crystalline deposits, perifoveal retinal whitening, and a foveal appearance similar to that of a 
lamellar macular hole.
Type IIB consisted of only two patients who were brothers aged nine and 12. Both presented with bilateral SRNV 
and subtle juxtafoveal telangiectasia, but without right angle veins, crystalline deposits, or pigmented plaques.
Type III
Occlusive capillary dropout along with retinal telangiectasia characterized Type III. All had minimal exudation and 
edema. Type IIIA consisted of three women aged 41 to 59, all with bilateral findings. Their visual acuity ranged from 
20/20 to 20/50. One reported polycythemia vera, another gout, and a third hyperglycemia. Type IIIB consisted of 
five men aged 35 to 41 all with CNS disorders. Two of them were brothers. 
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YANUZZI ET AL. CL ASSIFICATION
In 2006, Yanuzzi et al. proposed a simpler classification based on clinical, FA, and optical coherence tomography 
(OCT) findings in patients with IJT. Again there were three main categories, but without subsets in each main divi-
sion. They referred to Type I as “aneurysmal telangiectasia”, Type II as “perifoveal telangiectasia”, and Type III as 
“occlusive telangiectasia”. Similar to Gass and Blodi, Yanuzzi et al. further divided Type II into stages, but only two 
instead of five: Non-proliferative and proliferative.4
Type I – Aneurysmal Telangiectasia
Yanuzzi et al. reclassified Type IA and IB to “aneurysmal telangiectasia.” In this study, those with less than two clock 
hours of telangiectasia eventually progressed to having more extensive involvement. Therefore, they felt that Type 
IB was just an earlier presentation of Type IA (Figure 1). 
There were 10 patients (nine men, one female) in the report with aneurysmal telangiectasia with an average age of 
56. All but the female patient displayed unilateral findings consistent with those reported by Gass and Blodi, such as 
easily visible telangiectasia, exudation, and macular edema. OCT confirmed the presence of macular edema. Once 
again there were no findings of neovascularization, pigment proliferation, or crystalline deposits, and there was 
minimal ischemia.
Type II – Perifoveal Telangiectasia
“Perifoveal telangiectasia” replaced both Type IIA and Type IIB. Yanuzzi et al. believed Type IIB to be a familial 
abnormality as there had been no other reported cases in the literature. They also found that not all patients went 
through each stage of Type II previously described by Gass and Blodi, and so they categorized Type II into prolifera-
tive and non-proliferative based on the presence or absence of SRNV. 
Perifoveal telangiectasia patients in this study consisted of 11 males and 15 females with an average age of 59. Clini-
cal and FA findings were similarly consistent with those seen by Gass and Blodi (Figure 2). All cases were bilateral, 
but again with some asymmetry. Early signs included mild loss of retinal transparency and mild perifoveal retinal 
whitening without obvious telangiectasia which appeared later in the disease. Also seen in some were pigment 
plaques, crystalline deposits, and right angle vessels which Yanuzzi et al. explained could be arteriolar or venular 
in origin (Figures 3 and 4). 
Optical coherence tomography findings provided enlightening insight into perifoveal telangiectasia. Even though 
the FA showed late staining, OCT confirmed the absence of intraretinal edema. Cystic retinal spaces often bordered 
anteriorly by the internal limiting membrane (ILM) were present, but they were not secondary to edematous leak-
age. Instead, they resulted from retinal atrophy. Yanuzzi et al. called these spaces inner lamellar cysts with ILM 
drape (Figure 5). Optical coherence tomography also revealed a progressive loss of the outer retina along with pho-
toreceptor atrophy (Figure 6). The level of atrophy correlated with the patients’ visual acuities. Pigmentary plaques 
appeared as nonspecific subretinal reflectance with posterior shadowing. The crystalline deposits were too small 
to image with OCT. In the event of SRNV, resultant macular edema, hemorrhage, macular detachment, or fibrosis 
could also be visualized with OCT. 
Due to the apparent features of Type II IJT seen with OCT imaging, some suggest new grading criteria based 
on OCT findings.5,6 In addition to Yanuzzi et al.’s OCT findings, additional reports describe early retinal changes 
using macular pigment optical density, confocal scanning laser ophthalmoscope, and fundus autofluorescence 
(FAF).7 According to some, FAF may detect the earliest signs of Type II IJT due to macular pigment break-
down which allows increased autofluorescence to show through from the underlying retinal pigment epithelium 
(RPE).8,9 It eventually affects the RPE itself and causes an increase in both lipofuscin and subsequent autofluo-
rescence (Figure 7). Further release of disrupted RPE pigment causes a blocking effect and leads to a mottled 
appearance of both hyper- and hypo-fluorescence.8,9
Type III – Occlusive Telangiectasia
Yanuzzi et al. did not include any Type III or occlusive telangiectasia cases in their report. They believed it to 
be primarily an ischemic foveal disease with compensatory changes in the capillary bed, and argued that it be 
omitted from the macular telangiectasia classification as it is an ocular manifestation of systemic or cerebral 
familial disease. 
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PROPOSED ETIOLOGIES
Type I IJT is thought to be a congenital malformation of the retinal vasculature which allows for leakage of fluid 
and exudation from the capillary vessels.3,4 As mentioned previously, edema is the main cause of vision loss in these 
patients. Yanuzzi et al. and Gass and Blodi both considered that Type I IJT or aneurysmal telangiectasia could be 
a more focal variant of Coat’s disease and that perhaps they exist on a spectrum of diseases caused by congenital 
retinal telangiectasia formation. 
Figure 5: SD-OCT of an intraretinal cyst with overlying ILM drape and underlying photoreceptor damage. 
Figure 6: SD-OCT reveals outer retinal atrophy.
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Type II IJT may be an acquired condition in which the malformations of the retinal vasculature present later in 
life.3,4 A histological study performed by Green et al. on a patient with Type II IJT showed narrowing of the vessel 
lumen versus the telangiectatic or dilated appearance noted clinically and on FA. Increased width of the basement 
membrane along with degeneration of pericytes and endothelial cells led to thickening of the retinal capillaries. 
The authors conceived that breaks in the endothelium allowed fluorescein to leak into the thickened capillary walls 
which accounted for the late staining seen on FA. This report also found that capillary proliferation extended into 
the outer retinal layers down to the photoreceptors.10 A different histopathological report from a more advanced 
case of Type II IJT with SRNV did show dilation of retinal capillaries that reached into the outer retinal layers and 
subretinal space. Pigment migration also occurred along the course of the proliferating vessels.11
Figure 7: FAF details an area of central hypofluorescence corresponding to the pigment plaque surrounded by  
a hyperfluorescent ring indicating tissue degradation.
Speculation exists on whether the capillary abnormalities are the initial step in a process that leads to nutritional 
and metabolic damage to the retina, or if there is some sort of retinal change that precedes and leads to the forma-
tion of the abnormal capillaries. Müller cells garner the most suspicion due to their importance in maintaining 
proper health of the vasculature endothelium and sensory retina.12,13 A primary dysfunction in these cells may lead 
to capillary abnormalities and retinal atrophy, with the superficial crystalline deposits representing remnants of 
degenerated Müller cells.14
SRNV formation appears to stem from proliferation and anastomoses that exist within the blood vessels of the retina. 
This differs from the retino-choroidal anastomoses found in macular degeneration. The reason for retinal capillary 
proliferation is unclear, but photoreceptor atrophy may give the capillaries easier access to the subretinal space.15 
TREATMENT OPTIONS
Treatments for Type I IJT, or aneurysmal telangiectasia, aim at the destruction of the abnormal capillaries and 
aneurysms with photocoagulation or photodynamic therapy (PDT); or the stabilization of the blood retinal barrier 
with injectable medications. Limited options exist for those with Type II IJT due to the non-edematous nature of 
the disease, unless SRNV forms. Then treatments include laser photocoagulation, PDT, intravitreal triamcinolone 
injections, and intravitreal anti VEG-F agents.
Photocoagulation
Photocoagulation benefitted only those with Type I IJT, as noted by both Gass and Owakawa; and Gass and Blodi in 
their respective reports. They found a potential improvement in vision and exudation with photocoagulation. The 
procedure proved to be non-beneficial in those with Type II IJT.3,16 
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Photodynamic Therapy
Photodynamic therapy has also shown potential for improvement in vision, exudation, and edema in those with 
Type I IJT.17The benefits in Type II IJT, however, are limited to those with SRNV. Several reports show decreased 
leakage on FA as well as potential improvement or stabilization in vision in those with Type II with SRNV treated 
with PDT.18,19,20,21 Even though there is no frank visual improvement in many of these cases, it is important to re-
member that non-treated SRNV has very poor visual prognosis with 80% having final visual acuities of worse than 
20/200.22 In those with Type II IJT without SRNV, treatment with PDT temporarily improved leakage on FA, but 
did not improve visual acuity.23
Intravitreal Injections
Injection of intravitreal triamcinolone decreases leakage in Type I IJT and Type II IJT both with and without 
SRNV. Some report improvement in both macular edema as shown with OCT and in vision in those with Types I 
and II IJT with SRNV. However, one must consider the high side effect profile with steroid injections. Additionally, 
even though leakage improves on FA in Type II IJT without SRNV, there is no improvement in retinal thickness 
with OCT or visual acuity in these cases. The effects of treatment in those who do show improvement are short lived 
with recurrent fluid leakage in three to six months.24,25
Similar to intravitreal triamcinolone, injection of anti VEG-F agents decrease FA leakage in Types I and II IJT 
with and without SRNV with a much more favorable side effect profile.26,27,28,29,30,31 Reports indicate improvement 
in macular edema, retinal thickness, and vision in Types I and II IJT with SRNV. In Type II IJT patients without 
SRNV, few cases recorded improvement in retinal thickness and visual acuity; however, the majority failed to note 
a benefit in those with Type II IJT without SRNV. Although treatment with anti VEG-F has not been consistently 
shown to improve vision in those with Type II without SRNV, it is postulated that since it does reduce leakage from 
the abnormal blood vessels, that long-term therapy could potentially slow retinal atrophy. However, VEG-F is also 
needed in a certain level to maintain retinal vasculature health, and it is possible that long-term therapy could actu-
ally exacerbate retinal cell death.32 
Due to the rare incidences of these conditions, most treatment studies available include a minimal number of 
patients or are even single case reports. Long-term follow up data is limited as well. Since there is such a poor 
untreated prognosis in those with SRNV in Type II, it is important to remember that stabilization of vision even 
without improvement could be a success in treatment. Additionally, substances that could slow the neurodegen-
erative process that appears to be taking place in Type II IJT are currently being investigated. One particular 
molecule, called ciliary neurotrophic growth factor, slows photoreceptor cell death in animal models and re-
cently demonstrated safety in phase 1 clinical trials in humans.33At this time, however, treatment is reserved for 
those with SRNV in Type II IJT. 
DIFFERENTIAL DIAGNOSES
Differential diagnosis for IJT should include other identifiable causes of macular telangiectasia such as dia-
betic retinopathy, retinal vein occlusion, carotid occlusive disease, radiation retinopathy, and others. Careful 
case history of potential systemic etiologies of retinal telangiectasia should be thoroughly considered. Diabetic 
retinopathy is likely the most commonly misattributed diagnosis for those with Type I IJT; however, the pres-
ence of fairly isolated, mostly temporal, unilateral retinal telangiectasia or hemorrhaging should raise a red 
flag for the diagnosis of Type I IJT. 
Type II IJT is less commonly confused with other causes of retinal telangiectasia as it most often presents with 
one or more of its classic findings of crystalline deposits, retinal pigment plaques, right angle veins, and outer reti-
nal atrophy. Due to the profound funduscopic appearance of the pigmented plaques and significant outer retinal 
atrophy on OCT, this condition can be confused with conditions such as age related macular degeneration (AMD), 
chronic or recurrent central serous retinopathy, toxic retinopathies from medications such as hydroxychloroquine, 
or retinal scarring from conditions such as presumed ocular histoplasmosis (POHS). Differentials in the formation 
of SRNV should include other conditions with a similar finding, such as wet AMD, POHS, polypoidal choroidal 
vasculopathy, and others.
VISUAL PROGNOSIS
Visual prognosis for IJT varies case to case. As discussed previously, vision loss in Type I IJT is related, at least 
initially, to the level of macular edema present, which can potentially show improvement with various treatment 
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modalities. However, due to the rarity of the condition, little information exists to determine long-term prognosis. 
The condition is a chronic one, and does require continued monitoring and possibly long-term treatment. 
Vision loss from Type II IJT develops due to atrophy of the outer retina and photoreceptors. Due to the location 
of retinal atrophy being temporal to the foveal center, visual acuity often remains good in these patients until 
the development of SRNV. Data from the MacTel Study group showed that 42% of all patients had visual acuity 
of 20/25 or better.34 However, this photoreceptor damage can create paracentral scotomas that lead to patient 
symptoms even with good retained visual acuity.35 Various reports demonstrate that even with acceptable visual 
acuity, patients become symptomatic for patient perceived metamorphopsia, decreased reading speed, and dif-
ficulty in reading – the latter of which being the most frequently reported initial symptom.36,37 These symptoms 
arise most commonly between the ages of 50 and 69. Exact values for long-term prognosis for Type II IJT varies 
between reports but patients do have increased risk for both decreased visual acuity as well as decreased quality 
of life from vision loss.38,39  
CONCLUSION
Diagnosis of IJT can be complicated by clinical appearances mimicking other conditions. For example Type I IJT 
can easily be confused with diabetic retinal changes. While treatment options for the complication of macular ede-
ma from Type I IJT are essentially the same as those for diabetic macular edema, it is still important to make the 
correct diagnosis. While systemic conditions should still be considered and ruled out, a patient with Type I IJT 
could have unwarranted psychological distress if told they have retinal complications from diabetes when they 
don’t have the disease. 
 Also, even though there is currently no known beneficial treatment in the case of Type II IJT without SRNV, 
it is still important to make an accurate assessment in order to educate patients properly about their condition 
and prognosis. Patients should be made aware that the condition is a progressive retinal disease which can lead 
to central vision loss, metamorphopsia, and paracentral scotomas. They also need to be thoroughly educated 
on how to properly monitor their vision monocularly, and to be examined periodically for SRNV. With proper 
understanding of IJT, optometrists can monitor these conditions appropriately, referring for additional treat-
ment when necessary. l
Table: Comparison of the Two IJT Classification Schemes
Type I IJT Type II IJT Type III IJT
Gass and Blodi Yanuzzi et al. Gass and Blodi Yanuzzi et al. Gass and Blodi Yanuzzi et al.
Subtypes IA and IB None IIA and IIB None IIIA and IIIB N/A
Gender 
prevalence
Male Male
IIA – None
IIB – Brothers 
None
IIIA – female 
IIIB – male 
N/A
Laterality Unilateral Unilateral Bilateral Bilateral Bilateral N/A
Stages No No IIA – yes (five) Yes (two) No N/A
Clinical 
findings
Both – easily 
visible retinal 
telangiectasia, 
exudation, 
macular edema 
IA > two 
clock hours of 
involvement
IB < two 
clock hours of 
involvement
Easily visible 
retinal 
telangiectasia, 
exudation, 
macular edema
Both – 
minimally 
visible to no 
observable 
telangectiasia
IA – Right 
angle veins, 
pigmented 
retinal plaques, 
superficial 
crystalline 
deposits, SRNV
Mild loss 
of retinal 
transperancy 
without 
obvious 
telangiectasia, 
pigment 
plaques, 
crystalline 
deposits, right 
angle vessels, 
SRNV
Occlusive 
capillary 
dropout, 
minimal 
exudation and 
edema
IIIB – 
associated CNS 
disorders
N/A
C A NA D I A N  JO U R NA L  o f  O P T O M E T RY    |    R EV U E  C A NA D I E N N E  D ’O P T O M É T R I E     VO L .  7 9   NO.  3 33
CLINICAL RESEARCHC
References
1. Gass, J. D., and R. T. Owakawa. “Idiopathic Juxtafoveolar Retinal 
Telangiectasis.” Archives of Ophthalmology 100.5 (1982): 769-80.
2. Issa, Peter Charbel, Mark C. Gillies, Emily Y. Chew, Alan C. Bird, Tjebo 
F. C. Heeren, Tunde Peto, Frank G. Holz, and Hendrik P. N. Scholl. 
“Macular Telangiectasia Type 2.” Prog Retin Eye Res 34 (2013): 49-77.
3. Gass, J. Donald M., and Barbara A. Blodi. “Idiopathic Juxtafoveolar 
Retinal Telangiectasis.” Ophthalmology 100.10 (1993): 1536-546.
4. Yannuzzi, Lawrence A. “Idiopathic Macular Telangiectasia.” Ar-
chives of Ophthalmology Arch Ophthalmol 124.4 (2006): 450. Web.
5. Cohen, Steven M., Mark L. Cohen, Fayssal El-Jabali, and Scott E. 
Pautler. “Optical Coherence Tomography Findings In Nonprolifera-
tive Group 2A Idiopathic Juxtafoveal Retinal Telangiectasis.” Retina 
27.1 (2007): 59-66.
6. Sanchez JG, Garcia RA, Wu L, Berrocal MH, Graue-Wiechers F, Rodri-
guez FJ, et al. “Optical coherence tomography characteristics of group 
2A idiopathic parafoveal telangiectasis.” Retina 27 (2007): 1214–20.
7. Helb, Hans-Martin, Peter Charbel Issa, Rob L. P. Van Der Veen, Tos 
T. J. M. Berendschot, Hendrik P. N. Scholl, and Frank G. Holz. “Ab-
normal Macular Pigment Distribution In Type 2 Idiopathic Macular 
Telangiectasia.” Retina 28.6 (2008): 808-16.
8. Bottoni F, Eandi CM, Pedenovi S, Staurenghi G. “Integrated clinical 
evaluation of Type 2A idiopathic juxtafoveolar retinal telangiecta-
sis.” Retina 30 (2010): 317–26.
9. Wong WT, Forooghian F, Majumdar Z, Bonner RF, Cunningham D, 
Chew EY. “Fundus autofluorescence in type 2 idiopathic macular 
telangiectasia: Correlation with optical coherence tomography and 
microperimetry.” Am J Ophthalmol 148 (2009): 573–83.
10. Green, W. Richard, H. A. Quigley, Z. De La Cruz, and Bruce Cohen. 
“Parafoveal Retinal Telangiectasis.” Retina 25.Supplement (2005): 
162-70. 
11. Eliassi-Rad, Babak, and W. Richard Green. “Histopathologic Study 
Of Presumed Parafoveal Telangiectasis.” Retina 19.4 (1999): 332. 
12. Powner, Michael B., Mark C. Gillies, Marina Tretiach, Andrew 
Scott, Robyn H. Guymer, Gregory S. Hageman, and Marcus Frut-
tiger. “Perifoveal Muller Cell Depletion in a Case of Macular Telan-
giectasia Type 2.” Ophthalmology 117.12 (2010): 2407-416.
13. Gass, JD. “Müller cell cone, an overlooked part of the anatomy of 
the fovea centralis: Hypotheses concerning its role in the patho-
genesis of macular hole and foveomacualr retinoschisis.” Arch 
Ophthalmol 117 (1999) 821–823.
14. Wu, Lihteh. “Multimodality Imaging in Macular Telangiectasia 2: 
A Clue to Its Pathogenesis.” Indian J Ophthalmol Indian Journal of 
Ophthalmology 63.5 (2015): 394.
15. Gass JD. “Chorioretinal anastomosis probably occurs infrequently 
in type 2A idiopathic juxtafoveolar retinal telangiectasis.” Arch 
Ophthalmol 121 (2003): 1345–6.
16. Park, Donald W., Howard Schatz, H. Richard Mcdonald, and Robert N. 
Johnson. “Grid Laser Photocoagulation for Macular Edema in Bilateral 
Juxtafoveal Telangiectasis.” Ophthalmology 104.11 (1997): 1838-846.
17. Kotoula, Maria G., Dimitrios Z. Chatzoulis, Constantinos H. Kara-
batsas, Aristoteles Tsiloulis, and Evangelia E. Tsironi. “Resolution 
of Macular Edema in Idiopathic Juxtafoveal Telangiectasis Using 
PDT.” Ophthalmic Surg Lasers Imaging Ophthalmic Surgery, Lasers, 
and Imaging 40.1 (2009): 65-67.
18. Snyers, Bernadette, Claire Verougstraete, Laurence Postelmans, Anita 
Leys, and Philip Hykin. “Photodynamic Therapy of Subfoveal Neovas-
cular Membrane in Type 2A Idiopathic Juxtafoveolar Retinal Telangi-
ectasis.” American Journal of Ophthalmology 137.5 (2004): 812-19.
19. Smithen, Lindsay M., and Richard F. Spaide. “Photodynamic Thera-
py and Intravitreal Triamcinolone for a Subretinal Neovasculariza-
tion in Bilateral Idiopathic Juxtafoveal Telangiectasis.” American 
Journal of Ophthalmology 138.5 (2004): 884-85.
20. Lee, Bailey L. “Bilateral Subretinal Neovascular Membrane In 
Idiopathic Juxtafoveolar Telangiectasis.” Retina 16.4 (1996): 344-45.
21. Potter, Michael J., Shelagh M. Szabo, Eleanor Y. Chan, and Andrew 
H.c Morris. “Photodynamic Therapy of a Subretinal Neovascular 
Membrane in Type 2A Idiopathic Juxtafoveolar Retinal Telangiec-
tasis.” American Journal of Ophthalmology 133.1 (2002): 149-51.
22. Engelbrecht, Nicholas E. “Neovascular Membranes Associated With 
Idiopathic Juxtafoveolar Telangiectasis.” Archives of Ophthalmology 
Arch Ophthalmol 120.3 (2002): 320. 
23. Lahitte, Ghislaine Ducos De, Salomon Y. Cohen, and Alain Gaudric. 
“Lack of Apparent Short-term Benefit of Photodynamic Therapy in 
Bilateral, Acquired, Parafoveal Telangiectasis without Subretinal 
Neovascularization.” American Journal of Ophthalmology 138.5 
(2004): 892-94.
24. Alldredge, Claron D., and Bruce R. Garretson. “Intravitreal Triam-
cinolone For The Treatment Of Idiopathic Juxtafoveal Telangiecta-
sis.” Retina 23.1 (2003): 113-16.
25. Wu, Lihteh, Teodoro Evans, J. Fernando Arévalo, María H. Berrocal, 
Francisco J. Rodríguez, María Hsu, and Juan G. Sánchez. “Long-Term 
Effect Of Intravitreal Triamcinolone In The Nonproliferative Stage Of 
Type Ii Idiopathic Parafoveal Telangiectasia.” Retina 28.2 (2008): 314-19.
26. Kovach, Jaclyn L., and Philip J. Rosenfeld. “Bevacizumab (Avastin) 
Therapy For Idiopathic Macular Telangiectasia Type Ii.” Retina 29.1 
(2009): 27-32.
27. Júnior, Otacílio Oliveira Maia, Maria Teresa Brizzi Chizzotti 
Bonanomi, Walter Yukihiko Takahashi, Vinícius Paganini Nasci-
mento, and Beatriz Sayuri Takahashi. “Intravitreal Bevacizumab 
for Foveal Detachment in Idiopathic Perifoveal Telangiectasia.” 
American Journal of Ophthalmology 144.2 (2007): 296-99.
28. Issa, P. C., R. P. Finger, F. G. Holz, and H. P N Scholl. “Eighteen-
month Follow-up of Intravitreal Bevacizumab in Type 2 Idiopathic 
Macular Telangiectasia.” British Journal of Ophthalmology 92.7 
(2008): 941-45.
29. Gamulescu, Maria-Andreea, Andreas Walter, Helmut Sachs, 
and Horst Helbig. “Bevacizumab in the Treatment of Idiopathic 
Macular Telangiectasia.” Graefes Arch Clin Exp Ophthalmol Graefe’s 
Archive for Clinical and Experimental Ophthalmology 246.8 (2008): 
1189-193.
30. García-Ben, A., F. Gómez-Ulla, and M.j. Rodriguez-Cid. “Intravit-
real Bevacizumab in the Treatment of Idiopathic Juxtafoveal Telan-
giectasis Type I.” Archivos De La Sociedad Española De Oftalmología 
(English Edition) 89.7 (2014): 269-71.
31. Nakhwa, Chinmayp, and Manavid Sindal. “Idiopathic Macular 
Telangiectasia Type 1 with Ruptured Retinal Arterial Macroaneu-
rysm Post Intravitreal Bevacizumab.” Middle East African Journal of 
Ophthalmology Middle East Afr J Ophthalmol 22.3 (2015): 396.
32.) Kupitz, Elke H., Tjebo F. C. Heeren, Frank G. Holz, and Peter Char-
bel Issa. “Poor Long-Term Outcome Of Anti-Vascular Endothelial 
Growth Factor Therapy In Nonproliferative Macular Telangiectasia 
Type 2.” Retina 35.12 (2015): 2619-626.
33. Chew, Emily Y., Traci E. Clemons, Tunde Peto, Ferenc B. Sallo, Avner 
Ingerman, Weng Tao, Lawrence Singerman, Steven D. Schwartz, 
Neal S. Peachey, and Alan C. Bird. “Ciliary Neurotrophic Factor for 
Macular Telangiectasia Type 2: Results From a Phase 1 Safety Trial.” 
American Journal of Ophthalmology 159.4 (2015): 659-666.
34. Clemons, Traci E., Marc C. Gillies, Emily Y. Chew, Alan C. Bird, 
Tunde Peto, Maria J. Figueroa, and Molly W. Harrington. “Baseline 
Characteristics of Participants in the Natural History Study of 
Macular Telangiectasia (MacTel) MacTel Project Report No. 2.” 
Ophthalmic Epidemiology 17.1 (2010): 66-73. 
35. Heeren, Tjebo F. C., Traci Clemons, Hendrik P. N. Scholl, Alan C. 
Bird, Frank G. Holz, and Peter Charbel Issa. “Progression of Vision 
Loss in Macular Telangiectasia Type 2.” Investigative Opthalmology 
& Visual Science Invest. Ophthalmol. Vis. Sci. 56.6 (2015): 3905.
36. Heeren, Tjebo F. C., Frank G. Holz, and Peter Charbel Issa. “First 
Symptoms And Their Age Of Onset In Macular Telangiectasia Type 
2.” Retina 34.5 (2014): 916-19.
37. Finger, Robert P., Peter Charbel Issa, Rolf Fimmers, Frank G. Holz, 
Gary S. Rubin, and Hendrik P. N. Scholl. “Reading Performance Is 
Reduced by Parafoveal Scotomas in Patients with Macular Telangi-
ectasia Type 2.” Investigative Opthalmology & Visual Science Invest. 
Ophthalmol. Vis. Sci. 50.3 (2009): 1366.
38. Watzke, Robert C., Michael L. Klein, James C. Folk, Samuel G. Farmer, 
Richard S. Munsen, Robert J. Champfer, and K. R. Sletten. “Long-Term 
Juxtafoveal Retinal Telangiectasia.” Retina 25.6 (2005): 727-35.
39. Lamoureux, Ecosse L., Rebecca M. Maxwell, Manjula Marella, 
Mohamed Dirani, Eva Fenwick, and Robyn H. Guymer. “The 
Longitudinal Impact of Macular Telangiectasia (MacTel) Type 2 on 
Vision-Related Quality of Life.” Investigative Opthalmology & Visual 
Science Invest. Ophthalmol. Vis. Sci. 52.5 (2011): 2520.
C A NA D I A N  JO U R NA L  o f  O P T O M E T RY    |    R EV U E  C A NA D I E N N E  D ’O P T O M É T R I E     VO L .  7 9   NO.  334
